Delayed
London S.E.
09:05:02 03/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
3.95
GBX
|
0.00%
|
|
+2.60%
|
+64.58%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
16.82
|
11.47
|
147
|
7.033
|
7.368
|
9.399
|
Enterprise Value (EV)
1 |
17.74
|
12.34
|
144
|
5.683
|
2.304
|
5.199
|
P/E ratio
|
17.3
x
|
-1.56
x
|
-67.1
x
|
-0.62
x
|
-2.21
x
|
-7.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.72
x
|
1.17
x
|
16.8
x
|
0.57
x
|
0.98
x
|
1.04
x
|
EV / Revenue
|
1.82
x
|
1.26
x
|
16.5
x
|
0.46
x
|
0.31
x
|
0.58
x
|
EV / EBITDA
|
140
x
|
13.8
x
|
-66.5
x
|
-1.04
x
|
-1.13
x
|
-
|
EV / FCF
|
-7.63
x
|
-7.68
x
|
-27.5
x
|
-1.21
x
|
-0.7
x
|
-7.43
x
|
FCF Yield
|
-13.1%
|
-13%
|
-3.64%
|
-82.8%
|
-143%
|
-13.5%
|
Price to Book
|
0.92
x
|
0.79
x
|
6.02
x
|
0.61
x
|
0.74
x
|
1.07
x
|
Nbr of stocks (in thousands)
|
1,26,959
|
1,50,387
|
1,82,570
|
1,82,682
|
2,37,685
|
2,37,951
|
Reference price
2 |
0.1325
|
0.0762
|
0.8050
|
0.0385
|
0.0310
|
0.0395
|
Announcement Date
|
23/09/19
|
14/07/20
|
13/07/21
|
12/09/22
|
03/08/23
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
9.759
|
9.819
|
8.735
|
12.33
|
7.546
|
9
|
EBITDA
1 |
0.1263
|
0.893
|
-2.165
|
-5.469
|
-2.046
|
-
|
EBIT
1 |
-0.2062
|
-0.3132
|
-2.932
|
-6.653
|
-2.528
|
-0.6
|
Operating Margin
|
-2.11%
|
-3.19%
|
-33.57%
|
-53.97%
|
-33.5%
|
-6.67%
|
Earnings before Tax (EBT)
1 |
1.183
|
-8.298
|
-3.54
|
-10.5
|
-3.252
|
-1.2
|
Net income
1 |
0.9742
|
-6.828
|
-2.104
|
-11.33
|
-3.172
|
-1.2
|
Net margin
|
9.98%
|
-69.54%
|
-24.09%
|
-91.93%
|
-42.04%
|
-13.33%
|
EPS
2 |
0.007660
|
-0.0490
|
-0.0120
|
-0.0620
|
-0.0140
|
-0.005000
|
Free Cash Flow
1 |
-2.326
|
-1.606
|
-5.244
|
-4.707
|
-3.305
|
-0.7
|
FCF margin
|
-23.83%
|
-16.36%
|
-60.04%
|
-38.18%
|
-43.8%
|
-7.78%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
23/09/19
|
14/07/20
|
13/07/21
|
12/09/22
|
03/08/23
|
-
|
Fiscal Period: March |
2024 S1
|
2024 S2
|
---|
Net sales
|
-
|
-
|
EBITDA
|
-
|
-
|
EBIT
|
-
|
-
|
Operating Margin
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-0.46
|
Net income
1 |
-0.698
|
-0.46
|
Net margin
|
-
|
-
|
EPS
2 |
-0.003000
|
-0.002000
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
23/11/23
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
1 |
0.92
|
0.87
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
2.99
|
1.35
|
5.06
|
4.2
|
Leverage (Debt/EBITDA)
|
7.298
x
|
0.9735
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2.33
|
-1.61
|
-5.24
|
-4.71
|
-3.31
|
-0.7
|
ROE (net income / shareholders' equity)
|
-1.55%
|
-2.91%
|
-11.3%
|
-39.3%
|
-29.1%
|
-6.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
0.1400
|
0.1000
|
0.1300
|
0.0600
|
0.0400
|
0.0400
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.69
|
2.15
|
2.82
|
1.48
|
0.15
|
0.2
|
Capex / Sales
|
27.61%
|
21.94%
|
32.34%
|
11.99%
|
2.03%
|
2.22%
|
Announcement Date
|
23/09/19
|
14/07/20
|
13/07/21
|
12/09/22
|
03/08/23
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +64.58% | 11.8M | | -2.29% | 12.56B | | -9.59% | 7.68B | | -1.29% | 5.29B | | +21.82% | 5.24B | | +0.02% | 4.57B | | -50.89% | 3.29B | | +6.42% | 2.6B | | -9.04% | 2.2B | | -8.29% | 1.79B |
Diagnostic & Testing Substances
|